Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMR-001
- Development stage
- Phase 2
- Lead developer
- Lisata Therapeutics
- Modality
- Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intra-coronary
01
Overview
AMR-001 is an autologous, bone marrow-derived, cell-based therapy enriched for CD34+CXCR4+ cells. It is designed as a pharmaceutical-grade product for the treatment of heart failure and acute myocardial infarction (AMI). The therapy involves isolating a population of stem/progenitor cells from the patient's own bone marrow, enriching them for CD34+CXCR4+ markers, and infusing them directly into the heart via intra-coronary catheter several days after an acute myocardial infarction. These cells are believed to act as a natural repair mechanism by homing to damaged cardiac tissue and supporting regeneration through paracrine effects and possibly direct tissue repair. The product was developed by Amorcyte (a subsidiary of NeoStem) and has been evaluated in Phase 2 clinical trials for its ability to reduce long-term complications following heart attack[1][2][4].
- Brand names
- AngioStem
- Other names
- NBS-10NBS10NBS 10CLBS 10CLBS10CLBS-10
02
Targets
CXCL12 (C-X-C motif chemokine ligand 12)
Beyond the preview
Go deeper on AMR-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMR-001.